The U.S. Food and Drug Administration placed a partial clinical hold on studies conducted by Gilead Sciences assessing the combination of magrolimab plus azacitidine due to concerns of unexpected serious adverse events between study arms.
mRNA vaccines trigger backup immune response; some cancer drugs may help
BNT162b2 (Pfizer and BioNTech), Cancer, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, COVID-19 Studies, COVID-19 Vaccines, Immune Response, Los Angeles, Malignancies, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Preliminary data, University of Pennsylvania (Penn)A new study may help explain why mRNA vaccines by Pfizer/BioNTech and Moderna are more effective at preventing hospitalizations and deaths than they are at preventing infection. In another study, preliminary data suggests certain cancer drugs may help protect patients with malignancies from being infected with the new coronavirus.
The U.S. Food and Drug Administration placed a clinical hold on Boston-based Aprea Therapeutics’ lymphoid malignancy trial after the regulatory agency expressed concerns regarding the safety and efficacy data from a previous myelodysplastic syndromes (MDS) study.
Researchers said a fresh examination showed a malformation on a Centrosaurus was a manifestation of osteosarcoma, an aggressive bone cancer, making this the first known example of a dinosaur afflicted by malignant cancer.
Century Therapeutics, a startup founded by Versant Ventures, launched with $250 million in hand and a focus on developing induced pluripotent stem cell-based therapies for the treatment of hematologic and solid malignancies.